Bristol-Myers Squibb is weighing sale of UPSA
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Bristol-Myers Squibb (BMS) is weighing up the potential sale of its France-based consumer healthcare operation, UPSA, and has launched a strategic review of the business to assess its future growth potential. Contrary to reports from Reuters, OTC bulletin understands that the New York-based biopharmaceutical giant has not yet made a decision on the future of the business.
You may also be interested in...
Japan's Taisho Establishes Global OTC Footprint With $1.6bn Acquisition of Bristol-Myers Squibb's UPSA
Taisho is striking out from its Asian base to create a global OTC player through the acquisition of Bristol-Myers Squibb's UPSA. The transaction will catapult it to the number-three spot in France and give it a foothold in a slew of important emerging markets.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.